公开(公告)号：US20230295340A1

公开(公告)日：2023-09-21

申请号：US18062377

申请日：2022-12-06

申请人： Minerva Biotechnologies Corporation

发明人： Cynthia Bamdad ,  Sanjeev Mahanta

IPC分类号： C07K16/30 ,  A61P35/00 ,  C12N5/09 ,  A61K39/00

CPC分类号： C07K16/3092 ,  A61P35/00 ,  C12N5/0693 ,  A61K39/001117 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C12N2501/998

摘要： The present describes monoclonal antibodies.

公开(公告)号：US20230287316A1

公开(公告)日：2023-09-14

申请号：US17992779

申请日：2022-11-22

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Gordana Vunjak-Novakovic ,  Andrea Califano ,  Peter Sims ,  Alan Chramiec ,  Ece Ozturk ,  Kacey Ronaldson ,  Keith Yeager ,  Diogo Teles

IPC分类号： C12M3/00 ,  C12M1/42 ,  C12M1/12 ,  C12N5/09

CPC分类号： C12M21/08 ,  C12M23/44 ,  C12M25/06 ,  C12M35/08 ,  C12N5/0693

摘要： Disclosed are systems and methods for culturing systemic bioengineered tumor models, including osteosarcoma cells or breast adenocarcinoma cells derived from patients. The model includes the tumor cells on host tissues such as bone, liver, lung, and heart tissue, wherein the bone, liver, lung, and heart tissue are separated by endothelial barriers. Beneath the endothelial barriers the tissues are connected via circulation containing secreted factors and cells (e.g., tumor/immune cells).

公开(公告)号：US11739053B2

公开(公告)日：2023-08-29

申请号：US16365532

申请日：2019-03-26

申请人： ID4PHARMA, LLC

发明人： Xiang-Qun Xie ,  Garson David Roodman ,  Kyaw-Zeyar Myint ,  Noriyoshi Kurihara

IPC分类号： C07C229/36 ,  C07D309/40 ,  C07C211/50 ,  C07C317/34 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07D241/44 ,  C07C229/14 ,  C07D487/04 ,  C07C235/48 ,  C07C251/76 ,  A61K31/137 ,  A61K31/351 ,  A61K31/495 ,  A61K31/519 ,  A61K31/15 ,  A61K31/498 ,  A61K45/06 ,  C07C249/16 ,  C07D309/32 ,  C07D475/08 ,  C12N5/09 ,  A61K31/216

CPC分类号： C07C229/36 ,  A61K31/137 ,  A61K31/15 ,  A61K31/216 ,  A61K31/351 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06 ,  C07C211/50 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07C229/14 ,  C07C235/48 ,  C07C249/16 ,  C07C251/76 ,  C07C317/34 ,  C07D241/44 ,  C07D309/32 ,  C07D309/40 ,  C07D475/08 ,  C07D487/04 ,  C12N5/0693

摘要： A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

公开(公告)号：US11713441B2

公开(公告)日：2023-08-01

申请号：US17958234

申请日：2022-09-30

申请人： Academia Sinica

发明人： Ying-Chih Chang

IPC分类号： G01N33/50 ,  C12N5/09 ,  C12M1/00

CPC分类号： C12M23/20 ,  C12N5/0693 ,  G01N33/5011 ,  G01N33/5088 ,  C12N2502/1164 ,  C12N2513/00 ,  C12N2533/32 ,  C12N2533/40 ,  C12N2533/50

摘要： The present disclosure provides methods of evaluating a therapeutic agent for cancer, and methods of cancer treatment.

公开(公告)号：US11692160B2

公开(公告)日：2023-07-04

申请号：US16349217

申请日：2017-11-10

申请人： THE ASAN FOUNDATION ,  UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION

发明人： Gi Seok Jeong ,  Changmo Hwang ,  Se-Jin Jang

IPC分类号： C12M3/06 ,  B01L3/00 ,  C12M3/00 ,  C12M1/32 ,  C12M1/00 ,  C12M1/12 ,  C12N5/00 ,  C12N5/09 ,  C12Q1/02 ,  C12M1/26

CPC分类号： C12M23/16 ,  B01L3/502761 ,  C12M1/26 ,  C12M1/32 ,  C12M3/06 ,  C12M21/08 ,  C12M23/12 ,  C12M23/50 ,  C12M25/00 ,  C12N5/0062 ,  C12N5/0693 ,  C12Q1/025 ,  B01L2300/0864 ,  B01L2300/0874 ,  C12N2513/00

摘要： The microfluidic chip according to an embodiment of the present invention may include a plate, a bridge channel formed in intaglio on one side of the plate, an inlet formed through the plate to communicate with one end of the bridge channel, an outlet formed through the plate to communicate with the other end of the bridge channel, and at least one well extending in an outward direction of the plate from the bridge channel to provide a space, wherein the bridge channel may be in the form of a curved line, a bent line, an arc, a circle, a spiral, or a polygon.

公开(公告)号：US20230204565A1

公开(公告)日：2023-06-29

申请号：US17785818

申请日：2020-12-23

申请人： The Regents of the University of California

发明人： Aparna Bhaduri ,  Elizabeth Di Lullo ,  Arnold R. Kriegstein

IPC分类号： G01N33/50 ,  C12N5/09 ,  C12N5/079

CPC分类号： G01N33/5011 ,  C12N5/0618 ,  C12N5/0693 ,  C12N2501/15 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2513/00

摘要： The present disclosure provides a brain organoid for culturing cancer cells for a prolonged period of time and methods for culturing cancer cells in a brain organoid for a period of time at least one week. The cancer cells may be primary cancer cells obtained from a cancer from a subject. The brain organoid may be generated from embryonic stem cells or induced pluripotent stem cells that are not transformed to render them oncogenic. In certain aspects, the cancer cells cultured in the brain organoid may be Protein Tyrosine Phosphatase Receptor Type Z1 (PTPRZ1) expressing cancer cells obtained from a cancer from a subject. Also provided are methods for inhibiting tumor invasion in a cancer of a nervous system by administering to a subject suffering from such cancer an inhibitor of the PTPRZ1 pathway and for screening for inhibitors of cancer cell growth and/or invasion.

公开(公告)号：US20230184743A1

公开(公告)日：2023-06-15

申请号：US17912313

申请日：2021-03-16

申请人： University of Southern California

发明人： Min Yu ,  Teng Teng ,  Ebony Flowers

IPC分类号： G01N33/50 ,  C12N5/09 ,  A61P35/00 ,  A61K31/519

CPC分类号： G01N33/5011 ,  G01N33/5044 ,  C12N5/0693 ,  A61P35/00 ,  A61K31/519 ,  G01N2500/10

摘要： The disclosure provides screening methods to identify small molecule compounds that can promote single circulating tumor cells (CTCs) proliferation, or alternatively inhibit proliferation by CTCs, and uses thereof, including as treatment options for cancer.

公开(公告)号：US20230122540A1

公开(公告)日：2023-04-20

申请号：US17932885

申请日：2022-09-16

申请人： Genentech, Inc.

发明人： Xin YE ,  Matthew Tsn-Wei CHANG

IPC分类号： C12N15/10 ,  C12N5/09 ,  C12Q1/6869

摘要： Cells in a given population often display heterogeneity that may affect how each cell responds to a particular treatment or growth condition. The methods described herein allow determination of which cells from an initial population survive a treatment or condition, and how surviving cells evolve over time. For example, the methods described herein may be used to model drug resistance, response and/or adaptation in a cell population.

公开(公告)号：US20230076866A1

公开(公告)日：2023-03-09

申请号：US17983420

申请日：2022-11-09

申请人： ZHEJIANG UNIVERSITY

发明人： Jie JIN ,  Fenglin LI ,  Huafeng WANG ,  Honghu ZHU ,  Xin HUANG ,  Yi ZHANG ,  Chao HU ,  Shanshan SUO

IPC分类号： G01N33/50 ,  C12N5/09

摘要： The present application discloses a human T-lymphoblastic leukemia/lymphoma cell strain named as ZYXY-T1, and its construction method and use thereof. It was conserved in China Center for Type Culture Collection (Wuhan, China) on Jan. 20, 2021, and the preservation number was CCTCC NO: C202143. The present application is obtained by separating mononuclear cells from peripheral blood of one ETP-ALL patient, and culturing the cells in vitro for continuous natural passage. The strain has the typical surface antigen expression characteristics of ETP-ALL, that is, it does not express CD1α, CD5 or CD8, and highly expresses a stem cell marker CD34, and has good proliferation ability in vitro and tumorigenesis ability in vivo; it can be used as a cell material to study the occurrence and development mechanism of ETP-ALL, and can also be used to screen and evaluate ETP-ALL drugs to guide clinical medication.

公开(公告)号：US20230040280A1

公开(公告)日：2023-02-09

申请号：US17705166

申请日：2022-03-25

申请人： Andes Biotechnologies Global, Inc.

发明人： Luis O. Burzio Eriz ,  Veronica A. Burzio Menendez ,  Jaime E. Villegas Olavarria

IPC分类号： C12N15/113 ,  C12N5/09 ,  A61K31/7088 ,  A61K45/06 ,  A61K31/7105

摘要： The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).